Why More Women Seem to Be Growing Beards: What Dermatologists and Endocrinologists Say About Hirsutism, Causes, and Treatment

Table of Contents

1. Key Highlights:
2. Introduction
3. What hirsutism is — and how hair biology determines appearance
4. Common medical causes: PCOS leads the list
5. Medications, topical agents and environmental contributors
6. How clinicians evaluate facial hair: practical steps
7. Treatment options: individualizing care
8. When rapid onset or virilization appears: red flags that demand urgent evaluation
9. Skincare hype and the role of social media: separating signals from noise
10. The social and psychological impact: more than skin deep
11. Real-world examples that clarify causes and outcomes
12. Practical advice for people noticing increased facial hair
13. Costs, accessibility and equity in treatment
14. Research gaps and public-health priorities
15. How regulators and clinicians can respond to public concerns
16. The balance between medicalization and dignity
17. Final practical checklist: What to bring to your first appointment
18. FAQ

Key Highlights:

• A recent viral clip from Kenyan personality Dr Ofweneke sparked renewed attention to a visible rise in facial hair among women; clinicians point to hirsutism — driven primarily by excess androgens — as the medical explanation in many cases.
• Causes range from common endocrine conditions like polycystic ovary syndrome (PCOS) and menopause-related hormonal shifts to medication effects, topical contamination, and environmental endocrine disruptors; assessment requires clinical scoring, targeted blood tests, and imaging when onset is rapid.
• Effective responses combine medical therapy (combined oral contraceptives, anti-androgens, topical agents), hair-removal technology (laser, electrolysis), lifestyle measures and sensitive psychosocial support; urgent evaluation is warranted for rapid virilization or markedly abnormal hormone levels.

Introduction

A brief video clip from Kenyan comedian and media figure Dr Ofweneke stirred public conversation when he asked why more women appear to be growing beards. The question landed like a probe into a broader social and medical issue: when does visible facial hair in women reflect a benign, common variation, and when does it signal an underlying hormonal disorder or external exposure?

Facial hair on women spans a wide spectrum — from the faint, light vellus hairs almost everyone has, to coarse, male-pattern terminal hair. When that hair follows a male distribution pattern on the upper lip, chin, chest or back, clinicians call it hirsutism. The condition sits at the intersection of endocrinology, dermatology, culture and identity, which is why a short social-media prompt quickly triggered a complex debate. Practical answers demand careful distinctions: about hair biology, measurable causes, how clinicians assess severity, and which treatments work best for different scenarios.

This article explains the mechanisms that produce male-pattern hair growth in women, examines the leading medical and environmental drivers, outlines diagnostic pathways and evidence-based treatments, and addresses the social and psychological dimensions. Real-world examples show how diverse causes produce similar appearances, and why a thoughtful, clinical approach matters for both health and dignity.

What hirsutism is — and how hair biology determines appearance

Hair exists in several types. Vellus hairs are fine, unpigmented and cover most of the body. Terminal hairs are thicker, longer and pigmented; they form the beard, chest hair, and scalp hair typical of men after puberty. The transformation of vellus into terminal hair depends largely on androgen action at the hair follicle.

Androgens are a family of steroid hormones that include testosterone and dihydrotestosterone (DHT). All women produce small amounts of androgens from the ovaries and adrenal glands. Hair follicles respond differently depending on their location and genetic programming. Where follicles are androgen-sensitive, increased androgen exposure increases hair shaft diameter and pigment, producing terminal hair in formerly vellus-bearing regions — the clinical pattern recognized as hirsutism.

Clinically, hirsutism is measured rather than guessed. The Ferriman-Gallwey scoring system assigns scores to nine androgen-sensitive body areas; a total score above a population-specific threshold suggests hirsutism. Prevalence estimates vary by population and ethnicity, with roughly 5–15% of women affected depending on criteria and group studied. Some groups show higher baseline hair density, so evaluations must respect ethnic variation rather than treating every facial hair as pathological.

Genetics sets a baseline: families and ethnic groups differ in hair distribution and in the sensitivity of hair follicles to androgens. That is why some women naturally carry more facial hair without any endocrine abnormality. Distinguishing genetic predisposition from new-onset hormonal change is central to evaluation.

Common medical causes: PCOS leads the list

Polycystic ovary syndrome (PCOS) is the most common identifiable cause of hirsutism in women of reproductive age. PCOS is a heterogeneous disorder defined by combinations of irregular ovulation, androgen excess and polycystic ovarian morphology. Between 6% and 12% of women of reproductive age meet diagnostic criteria for PCOS, depending on the definition used. Many women with PCOS have mild-to-moderate hirsutism driven by relative overproduction of ovarian androgens and insulin resistance.

Other endocrine causes merit attention because they are less common but often more urgent:

• Adrenal disorders. Adrenal tumors that secrete androgens are rare but can produce rapid, severe virilization and markedly elevated dehydroepiandrosterone sulfate (DHEA‑S) levels. Non-tumoral adrenal hyperplasia can also raise androgen production.
• Cushing’s syndrome. Excess cortisol — from adrenal or pituitary sources — can produce hirsutism among a constellation of other findings such as weight gain, purple striae, and muscle weakness.
• Hyperprolactinemia and thyroid disease. These can influence menstrual function and, in some cases, hair patterns. Thyroid dysfunction more typically causes hair thinning than hirsutism, but evaluation often includes thyroid function tests because these systems intersect.
• Ovarian or adrenal tumors. Rapid onset of coarse terminal hair, voice deepening, clitoromegaly, and large increases in circulating testosterone should prompt urgent imaging to exclude androgen-secreting tumors.

Menopause changes the equation. Absolute androgen levels decline with age, but estrogen production falls even more sharply, producing a relative androgen excess that can lead to increased facial hair for some women. The pattern is often milder and more gradual than the abrupt virilization caused by a tumor.

Medications, topical agents and environmental contributors

The causes of increased facial hair are not purely internal. Several medications, topical exposures and environmental compounds can provoke excess hair growth.

Medications known to cause hirsutism or hypertrichosis (a broader term that includes generalized hair thickening rather than male–pattern distribution) include anabolic-androgenic steroids, testosterone therapy, danazol (used for endometriosis), and some immunosuppressants. Conversely, drugs such as phenytoin and minoxidil can produce unwanted hair growth in treated or adjacent areas: topical minoxidil for hair loss, if inadvertently applied to the face or transferred from pillowcases, can generate localized hypertrichosis.

Topical hormonal contamination is an important but under-appreciated pathway. Testosterone-containing creams or gels that contact skin can cause localized hair growth in women who handle them, and transfer to partners or children can produce effects in those exposed. There are clinical reports of infants and partners developing virilizing changes from secondary exposure to topical testosterone.

Cosmetics and skincare products sometimes contain impurities or additives with endocrine activity. The phrase “endocrine disruptor” covers compounds that interfere with hormone action. Phthalates, bisphenol A (BPA), certain parabens and some pesticides have been associated in animal and epidemiologic studies with altered reproductive hormone signaling. Evidence in humans is complex and often inconsistent, but the possibility of subtle, population-level endocrine effects invites scrutiny — especially when exposure begins in utero or in early life.

Anecdotal reports — like those asked about by Dr Ofweneke — that attribute rising facial hair to particular face creams or beauty regimens occasionally surface on social media. Some of these reports implicate contaminated or counterfeit products that include steroids or androgenic compounds. When a previously hairless area develops coarse hair after using a particular topical product, clinicians investigate for contamination or inadvertent exposure.

Weather does not cause beard growth per se. Climatic changes might alter skin physiology or influence product usage patterns, but there is no plausible mechanism by which temperature or humidity alone converts vellus to terminal hair. The explanation is more likely hormonal, genetic, pharmacologic or chemical exposure.

How clinicians evaluate facial hair: practical steps

A methodical assessment distinguishes longstanding, genetic hair patterns from new, pathologic changes requiring investigation.

1. Clinical history
   • Onset and tempo. Gradual changes over years suggest PCOS or genetics; rapid onset over weeks to months with virilizing features suggests an androgen-secreting tumor.
   • Menstrual history. Irregular periods or amenorrhea point toward PCOS or other endocrine disruption.
   • Medication and topical exposure history. Include supplements, herbal remedies, topical creams and contact with others using hormone therapies.
   • Family history. Male-pattern hair in female relatives suggests a genetic predisposition.
   • Associated symptoms. Acne, alopecia, voice changes, increased muscle mass, or changes in libido inform the differential.
2. Physical examination
   • Ferriman-Gallwey scoring quantifies hirsutism severity by scoring nine anatomic sites.
   • Look for virilization signs (deepened voice, clitoromegaly, rapid muscularity).
   • Note obesity, acanthosis nigricans (a marker of insulin resistance), central fat distribution, striae or other systemic signs.
3. Laboratory testing
   • Early-morning total and free testosterone (sensitive assays are preferred).
   • DHEA‑S to evaluate adrenal androgen production.
   • LH/FSH ratio and other markers when PCOS is suspected.
   • TSH and prolactin to exclude thyroid disease and pituitary involvement.
   • Metabolic evaluation for insulin resistance, glucose intolerance and lipids in suspected PCOS. Markedly elevated testosterone or DHEA‑S levels require prompt imaging to search for tumors.
4. Imaging
   • Pelvic ultrasound to assess ovarian morphology and exclude masses.
   • Adrenal imaging (CT or MRI) when DHEA‑S is high or adrenal tumor is suspected.

This measured approach reduces unnecessary testing in women with mild, stable hirsutism while not missing rare but serious causes.

Treatment options: individualizing care

Hirsutism often prompts women to seek cosmetic relief, but medical therapy plays a central role when androgen excess is present. Treatment choices depend on cause, degree of hair growth, patient preferences, reproductive plans and skin type.

Principles of management

• Address the underlying cause when one is identifiable and treatable.
• Combine systemic therapy to reduce hair growth with local hair removal methods for faster improvement.
• Set realistic expectations. Hair response is slow; hair cycles are long, and treatments may reduce growth without eliminating every hair.

Medical therapies

• Combined oral contraceptives (COCs). For many reproductive-age women with androgen excess, COCs are first-line. They suppress ovarian androgen production and increase sex-hormone binding globulin, lowering free testosterone. Benefits often become apparent after three to six months.
• Anti-androgens. Spironolactone blocks androgen receptors and reduces androgen production; typical doses range from 50 to 200 mg daily. Treatment requires contraception because of teratogenic risk if pregnancy occurs on anti-androgens. Side effects include menstrual irregularities and hyperkalemia; periodic monitoring is recommended.
• 5α-reductase inhibitors (finasteride). These interfere with conversion of testosterone to DHT and can be effective in some women; contraindicated in pregnancy.
• Eflornithine hydrochloride cream (topical). Marketed as Vaniqa, it slows facial hair growth by inhibiting an enzyme in hair follicles. Effects are modest and reversible; creams must be applied continuously for benefit.
• Metformin. For women with PCOS and insulin resistance, metformin improves metabolic parameters and can reduce hyperandrogenic symptoms indirectly, though a direct anti-hirsutism effect is variable.
• Flutamide, cyproterone acetate and other agents. Some potent anti-androgens are effective but are limited by side effects such as liver toxicity or are not available in all countries.

Hair removal and cosmetic procedures

• Shaving, plucking and waxing. Immediate and inexpensive but can increase inflammation and ingrown hairs, and hair regrows.
• Bleaching. Does not remove hair but reduces contrast between hair and skin, making hair less noticeable.
• Depilatories. Chemical hair removers dissolve hairs but can irritate sensitive facial skin.
• Laser hair removal. Laser and intense pulsed light (IPL) target pigment in hair follicles during active growth phases. Laser is most effective on dark, coarse hairs and less so on light or grey hair. Multiple sessions spaced weeks apart are necessary. Skin type matters: certain lasers are safer on darker skin tones, and pigmentary changes are a risk to manage.
• Electrolysis. The only method recognized as permanently destructive to hair follicles when performed properly. It is time-consuming and can be costly for areas with many hairs.
• Combined approach. Many women use a combination: systemic therapy to reduce new growth plus laser or electrolysis to remove existing terminal hairs.

Choosing the right strategy The best approach depends on hair color and skin tone, hair density, and patient preferences about cost, convenience and permanence. Laser suits those with dark hair and lighter skin or with modern lasers adapted for darker skin. Electrolysis is hair-color independent and remains the definitive option for those seeking permanent removal. Topical eflornithine can soften and slow growth but does not remove hair.

When rapid onset or virilization appears: red flags that demand urgent evaluation

Most hirsutism is gradual and not an emergency. Rapid progression over weeks to a few months, especially when accompanied by signs of virilization — deepened voice, clitoromegaly, sudden menstrual cessation, rapid muscle development — calls for immediate workup. Such a profile raises the possibility of an androgen‑secreting ovarian or adrenal tumor, both of which require prompt imaging and specialist referral.

Markedly elevated androgen measurements in blood tests are another red flag: clinicians use hormone levels to decide whether to pursue adrenal or ovarian imaging, and to gauge urgency.

Skincare hype and the role of social media: separating signals from noise

Public figures and comedians asking blunt questions about changing appearance do the useful work of opening conversation. Social media multiplies anecdote, however, and anecdotes can mislead. A cream that someone used before hair growth might be blamed incorrectly if a hormonal condition was already evolving.

That said, social media has an accountability function. Investigations of contaminated cosmetics and counterfeit products have uncovered formulations with corticosteroids or other additives that produce unexpected skin or hair changes. Regulatory agencies intervene when evidence supports contamination risks. Consumers benefit from buying reputable brands, checking product registration where available, and avoiding unverified “miracle” preparations.

Clinicians increasingly see patients who arrive with screenshots, product lists and self-collected timelines. That documentation can be invaluable in linking topical exposures to new signs, particularly when hair growth is localized to the site of application.

The social and psychological impact: more than skin deep

Facial hair intersects with gender norms and identity. For many women, excessive facial hair is a source of shame, embarrassment and social withdrawal. Studies link hirsutism to reduced quality of life, increased anxiety and depression, and lowered self-esteem. How society frames facial hair — as deviant, as a cosmetic problem, or as normal diversity — shapes the experience of women affected by hirsutism.

Movements that emphasize body acceptance and visibility for gender-nonconforming expressions have expanded the conversation. Activists like Harnaam Kaur, a British woman living with polycystic ovary syndrome who chose to keep her beard, have challenged norms and promoted mental-health-centred approaches. At the same time, many women prefer removal and seek medical help to reduce hair for comfort and social ease. Both positions deserve respect; clinicians must support patient autonomy.

Media commentary that ridicules or fetishizes women with facial hair perpetuates stigma and discourages help-seeking. When public figures ask questions, as Dr Ofweneke did, the ideal response is informed, respectful and anchored in clinical understanding — acknowledging the medical causes while recognizing the lived experience.

Real-world examples that clarify causes and outcomes

• PCOS-driven hair growth. A 28-year-old woman presents with gradual chin and upper-lip hair over several years and irregular periods. Examination finds a Ferriman-Gallwey score consistent with mild-to-moderate hirsutism and pelvic ultrasound shows polycystic ovaries. She starts a combined oral contraceptive and eflornithine cream while planning laser sessions; over six months hair density decreases and menstrual cycles regularize.
• Medication-induced hypertrichosis. A patient treated with systemic minoxidil for a cardiovascular indication notices increased facial hair. Discontinuation of the medication reduces the unwanted hair over subsequent months, illustrating a reversible pharmacologic cause.
• Topical contamination. Case series have documented instances where counterfeit or adulterated skin-lightening creams contained corticosteroids or other active agents producing irregular hair growth and skin changes; regulatory action removed such products once identified.
• Rapid virilization due to tumor. A woman in her 40s develops a rapidly deepening voice, sudden coarse facial hair, and menstrual cessation. Blood tests reveal markedly elevated testosterone; imaging identifies an adrenal mass. Surgical removal confirms an androgen-secreting tumor; the virilizing features stabilize post-operatively, underscoring the importance of urgent evaluation with red-flag signs.

These examples illustrate the range of causes and outcomes, and why tailored evaluation is essential.

Practical advice for people noticing increased facial hair

• Track onset and tempo. Note when the hair began and how quickly it intensified. Fast change suggests a different evaluation than slow, long-standing hair.
• Record menstrual patterns. Irregular cycles frequently accompany PCOS and should be discussed with your clinician.
• Review medications, supplements and topical products. Bring a list or photos to your appointment.
• Seek a clinical assessment rather than relying on internet self-diagnosis. Primary-care clinicians, dermatologists and endocrinologists collaborate in this area.
• If you are planning pregnancy or are pregnant, discuss safety: many anti-androgenic medications are teratogenic and require contraception during use.
• Address psychological impact. If facial hair causes distress, ask for referrals to mental-health services or peer-support groups; practical coping strategies and cosmetic interventions can reduce anxiety while medical work proceeds.

Costs, accessibility and equity in treatment

Access to effective care is uneven. Laser and electrolysis carry substantial costs and often fall outside insurance coverage. Anti-androgen medications require monitoring and sometimes specialist prescription. In many low- and middle-income settings, women rely primarily on shaving or topical bleaching because advanced therapies are unavailable or unaffordable.

Equity considerations also include skin tone. Historically, laser technologies worked best on lighter skin with darker hair; advances in laser design now offer safer options for darker skin, but access to appropriate technologies varies by region. Public-health strategies that address PCOS detection, affordable treatments and regulation of cosmetic markets can reduce disparities.

Research gaps and public-health priorities

The precise population-level trends in hirsutism are not well characterized. Anecdotal impressions that facial hair is increasing could reflect multiple factors: greater public visibility and reporting, shifting beauty norms and product use, environmental exposures, or true epidemiologic change. Priorities for research and policy include:

• Improved surveillance. Population studies that quantify changes in hair patterns and correlate them with reproductive-age trends, medication use, and environmental exposures.
• Exposure science. Better measurement of endocrine-disrupting chemicals in consumer products and longitudinal studies of their effects on human hormone systems.
• Regulatory oversight. Stronger controls to detect and remove contaminated or counterfeit cosmetic products — particularly creams marketed without transparent ingredients — would reduce avoidable harm.
• Access to care. Broader availability of evidence-based treatment options, including affordability for hair-removal procedures and anti-androgen medications, would address disparities.
• Psychosocial support research. Interventions to reduce stigma and to support women navigating hirsutism remain underdeveloped relative to the medical literature.

How regulators and clinicians can respond to public concerns

Public figures asking questions create an opportunity for health systems. Practical steps include:

• Rapid public education. Clear, accessible messaging from dermatology and endocrinology societies can correct misinformation and advise when to seek care.
• Product investigations. Regulatory bodies should prioritize complaints about sudden adverse effects linked to particular cosmetics and test samples for contamination.
• Training primary-care providers. Dermatologic and endocrine signals often present first to generalists; equipping them with clear pathways for testing and referral reduces delays.
• Supporting community resources. Peer-support networks, culturally sensitive counseling, and practical guides on safe hair removal reduce the social burden.

These measures combine clinical prudence with consumer protection.

The balance between medicalization and dignity

Not every woman with increased facial hair needs intensive medical workup; many will choose cosmetic management or body acceptance without medical treatment. The goal of clinical practice is not to pathologize difference but to identify treatable causes, manage endocrine disease where present, and support patient choice. That balancing act must be explicit in consultations: listen to the patient’s goals, present options with risks and benefits, and respect decisions about appearance and identity.

When a social-media prompt asks why beards among women appear more common, the right reply is multifaceted: acknowledge genetic and ethnic diversity in hair, explain the dominant medical mechanisms that convert vellus to terminal hairs, describe the red flags that require urgent investigation, and advise on effective, evidence-based options to reduce hair and address underlying disease.

Public discussion can destigmatize and direct people to care — provided it is anchored to medical fact and sensitivity.

Final practical checklist: What to bring to your first appointment

• A timeline documenting when you first noticed increased hair and how quickly it progressed.
• A record of menstrual patterns, weight changes, acne or other symptoms.
• A list of all medications, supplements and topical products used in the past year, including brand names and sources.
• Photographs showing progression over time, if available.
• Family history of similar hair patterns or endocrine disorders.
• Questions prepared in advance about testing, treatment options and possible side effects.

This information helps clinicians determine whether basic testing suffices or whether advanced imaging and specialty referral are necessary.

FAQ

Q: Is it actually happening — are more women growing beards now? A: There is no definitive, population-level evidence that women across the globe are uniformly growing beards at higher rates. Increased visibility on social media, changing beauty practices and greater willingness to discuss body hair publicly may create the impression of a rise. That said, individual clinics report increases in consultations about facial hair. Distinguishing true epidemiologic change from observational bias requires systematic study.

Q: What is the single most common cause of increased facial hair in women? A: Polycystic ovary syndrome (PCOS) is the most frequent identifiable cause of hirsutism in reproductive-age women. Genetic predisposition accounts for many cases too, where hair patterns are ethnically or familially typical without underlying disease.

Q: Can skincare products make women grow beards? A: Typical skincare ingredients do not cause terminal beard growth. However, creams contaminated with steroids or androgenic compounds, topical exposure to hormone-containing therapies (e.g., testosterone gels) and improper use or transfer of medications such as topical minoxidil can promote localized hair growth. Suspicion of a contaminated product warrants stopping the product and reporting the issue for investigation.

Q: Could environmental chemicals be responsible? A: Some environmental chemicals — labeled endocrine disruptors — have been linked in laboratory and epidemiologic studies to altered hormone signaling. Evidence in humans remains complex. If environmental chemicals play a role in shifting population-level hormone patterns, effects are likely gradual and mediated through multiple pathways; regulatory and research attention is needed.

Q: How do doctors decide whether to run tests? A: Evaluation is tailored to symptoms. Mild, stable hair that began in adolescence and has a strong family history may not require extensive testing. Rapid onset, severe hair growth, or signs of virilization prompt hormonal testing (testosterone, DHEA‑S, LH/FSH, TSH, prolactin) and imaging to exclude tumors.

Q: What removal methods are most effective? A: For permanent destruction, electrolysis is the established technique; it works on all hair colors but is time- and labor-intensive. Laser hair removal is highly effective for dark hairs, usually requires multiple sessions, and is faster for larger areas. Topical eflornithine can slow growth and is useful in combination with other methods. Systemic therapies reduce new hair growth but work slowly.

Q: Are hormonal treatments safe? A: Hormonal treatments carry risks and require monitoring. Combined oral contraceptives are commonly used and generally safe for many women. Spironolactone and finasteride reduce androgen effects but carry teratogenic risks and require reliable contraception for women of childbearing potential. Side effects and monitoring needs differ among medications; clinicians individualize therapy.

Q: When should someone seek urgent care? A: Seek prompt evaluation if facial hair appears rapidly over weeks to a few months, especially with deepening of voice, sudden menstrual cessation, clitoromegaly, or markedly increased muscularity. These could indicate an androgen-secreting tumor requiring urgent imaging.

Q: Can lifestyle changes help? A: For women with PCOS and insulin resistance, weight loss and exercise improve metabolic health and can reduce androgen-related symptoms. Lifestyle measures alone may not eliminate hirsutism but can enhance response to medical therapy and overall well-being.

Q: How should family and friends respond when someone raises concern about facial hair? A: Respond with respect and a non-judgmental attitude. Avoid ridicule. If the person seeks medical advice, encourage evaluation by a clinician. Recognize that choices differ; some women may pursue medical treatment, others may embrace the hair as part of their identity.

Q: What regulatory or consumer steps reduce risk from products? A: Buy products from reputable manufacturers and suppliers. Avoid black-market or “secret formula” creams. Report adverse effects to local health authorities. Regulatory agencies can then investigate suspected contamination.

Q: Is there hope for those distressed by facial hair? A: Yes. Many women experience meaningful improvement with combined medical and cosmetic strategies. Options are available for slowing hair growth, removing existing hair and addressing underlying endocrine disorders. Combining medical care with psychological support maximizes outcomes.

If increased facial hair concerns you or someone you care for, document the history, note any red-flag features, and consult a clinician who can guide testing and treatment with sensitivity to medical, cosmetic and psychosocial priorities.